A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model

Antiviral Research

Volumn 94, Issue 1, 2012, Pages 1-8

  Thibodeaux, Brett A ^a   Garbino, Nina C ^a   Liss, Nathan M ^c   Piper, Joseph ^a   Schlesinger, Jacob J ^b   Blair, Carol D ^a   Roehrig, John T ^c  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Human monoclonal antibodies; Prophylaxis; Treatment; Yellow fever

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2C9; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CHIMERA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FUSION; HUMAN; HUMAN CELL; IMMUNOPROPHYLAXIS; IN VITRO STUDY; MOUSE; MYELOMA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RNA EXTRACTION; SURVIVAL; VIRUS LOAD; VIRUS NEUTRALIZATION; YELLOW FEVER;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, 129 STRAIN; MICE, KNOCKOUT; YELLOW FEVER; YELLOW FEVER VIRUS;

FLAVIVIRUS; MOSQUITO-BORNE VIRUSES; MURINAE; MUS; YELLOW FEVER VIRUS;

EID: 84857990014     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.02.001     Document Type: Article

References (58)

1. Barnett E.D. Yellow fever: epidemiology and prevention. Clin. Infect. Dis. 2007, 44:850-856.
2. Barrett A.D., Gould E.A. Antibody-mediated early death in vivo after infection with yellow fever virus. J. Gen. Virol. 1986, 67(Pt 11):2539-2542.
3. Barrett A.D., Niedrig M., Teuwen D.E. International laboratory network for yellow fever vaccine-associated adverse events. Vaccine 2008, 26:5441-5442.
4. Barrett A.D., Teuwen D.E. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. Curr. Opin. Immunol. 2009, 21:308-313.
5. Beigel J.H., Nordstrom J.L., Pillemer S.R., Roncal C., Goldwater D.R., Li H., Holland P.C., Johnson S., Stein K., Koenig S. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrob. Agents Chemother. 2010, 54:2431-2436.
6. Brandriss M.W., Schlesinger J.J., Walsh E.E., Briselli M. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J. Gen. Virol. 1986, 67(Pt 2):229-234.
7. Cetron M.S., Marfin A.A., Julian K.G., Gubler D.J., Sharp D.J., Barwick R.S., Weld L.H., Chen R., Clover R.D., Deseda-Tous J., Marchessault V., Offit P.A., Monath T.P. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm. Rep. 2002, 51:1-11. quiz CE11-14.
8. Diamond M.S., Sitati E.M., Friend L.D., Higgs S., Shrestha B., Engle M. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 2003, 198:1853-1862.
9. Doblas A., Domingo C., Bae H.G., Bohorquez C.L., de Ory F., Niedrig M., Mora D., Carrasco F.J., Tenorio A. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J. Clin. Virol. 2006, 36:156-158.
10. Engel A.R., Vasconcelos P.F., McArthur M.A., Barrett A.D. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 2006, 24:2803-2809.
11. Ferguson M., Shin J., Knezevic I., Minor P., Barrett A. WHO Working Group on Technical Specifications for manufacture and evaluation of yellow fever Vaccines, Geneva, Switzerland, 13-14 May 2009. Vaccine 2010, 28:8236-8245.
12. Gaffo A., Saag K.G., Curtis J.R. Treatment of rheumatoid arthritis. Am. J. Health Syst. Pharm. 2006, 63:2451-2465.
13. Gardner C.L., Ryman K.D. Yellow fever: a reemerging threat. Clin. Lab. Med. 2010, 30:237-260.
14. Gould E.A., Buckley A. Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J. Gen. Virol. 1989, 70(Pt 6):1605-1608.
15. Gould E.A., Buckley A., Groeger B.K., Cane P.A., Doenhoff M. Immune enhancement of yellow fever virus neurovirulence for mice. Studies of mechanisms involved. J. Gen. Virol. 1987, 68(Pt 12):3105-3112.
16. Gubler D.J. Human arbovirus infections worldwide. Ann. NY Acad. Sci. 2001, 951:13-24.
17. Gubler D.J. The global emergence/resurgence of arboviral diseases as public health problems. Arch. Med. Res. 2002, 33:330-342.
18. Hackett J., Hoff-Velk J., Golden A., Brashear J., Robinson J., Rapp M., Klass M., Ostrow D.H., Mandecki W. Recombinant mouse-human chimeric antibodies as calibrators in immunoassays that measure antibodies to Toxoplasma gondii. J. Clin. Microbiol. 1998, 36:1277-1284.
19. Hunt A.R., Bowen R.A., Frederickson S., Maruyama T., Roehrig J.T., Blair C.D. Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection. Virology 2011, 414:146-152.
20. Hunt A.R., Frederickson S., Hinkel C., Bowdish K.S., Roehrig J.T. A humanized murine monoclonal antibody protects mice either before or after challenge with virulent Venezuelan equine encephalomyelitis virus. J. Gen. Virol. 2006, 87:2467-2476.
21. Hunt A.R., Frederickson S., Maruyama T., Roehrig J.T., Blair C.D. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS neglected tropical diseases 2010, 4:e739.
22. Johnson A.J., Martin D.A., Karabatsos N., Roehrig J.T. Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. J. Clin. Microbiol. 2000, 38:1827-1831.
23. Johnson A.J., Roehrig J.T. New mouse model for dengue virus vaccine testing. J. Virol. 1999, 73:783-786.
24. Johnson G., Wu T.T. Kabat database and its applications: 30years after the first variability plot. Nucleic Acids Res. 2000, 28:214-218.
25. Julander J.G., Morrey J.D., Blatt L.M., Shafer K., Sidwell R.W. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. Antiviral Res. 2007, 73:140-146.
26. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., Cetron M.S. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23:3256-3263.
27. Lee E., Lobigs M. E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence. J. Virol. 2008, 82:6024-6033.
28. Leget G.A., Czuczman M.S. Use of rituximab, the new FDA-approved antibody. Curr. Opin. Oncol. 1998, 10:548-551.
29. Lobigs M., Dalgarno L., Schlesinger J.J., Weir R.C. Location of a neutralization determinant in the E protein of yellow fever virus (17D vaccine strain). Virology 1987, 161:474-478.
30. Lupo L., Panzera P., Tandoi F., Carbotta G., Giannelli G., Santantonio T., Rendina M., Gentile A., Memeo V. Basiliximab versus steroids in double therapy immunosuppression in liver transplantation: a prospective randomized clinical trial. Transplantation 2008, 86:925-931.
31. Martin M., Weld L.H., Tsai T.F., Mootrey G.T., Chen R.T., Niu M., Cetron M.S. Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg. Infect. Dis. 2001, 7:945-951.
32. Massad E., Coutinho F.A., Burattini M.N., Lopez L.F., Struchiner C.J. Yellow fever vaccination: how much is enough?. Vaccine 2005, 23:3908-3914.
33. Mathews J.H., Roehrig J.T. Elucidation of the topography and determination of the protective epitopes on the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J. Immunol. 1984, 132:1533-1537.
34. Meier K.C., Gardner C.L., Khoretonenko M.V., Klimstra W.B., Ryman K.D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog. 2009, 5:e1000614.
35. Monath T.P. Yellow fever as an endemic/epidemic disease and priorities for vaccination. Bull. Soc. Pathol. Exot. 2006, 99:341-347.
36. Monath T.P. Treatment of yellow fever. Antiviral. Res. 2008, 78:116-124.
37. Monath T.P., Cetron M.S., McCarthy K., Nichols R., Archambault W.T., Weld L., Bedford P. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum. Vaccin. 2005, 1:207-214.
38. Morrey J.D., Siddharthan V., Olsen A.L., Roper G.Y., Wang H., Baldwin T.J., Koenig S., Johnson S., Nordstrom J.L., Diamond M.S. Humanized monoclonal antibody against West Nile Virus envelope protein administered after neuronal Infection protects against lethal encephalitis in hamsters. J. Infect. Dis. 2006, 194:1300-1308.
39. Morrey J.D., Siddharthan V., Olsen A.L., Wang H., Julander J.G., Hall J.O., Li H., Nordstrom J.L., Koenig S., Johnson S., Diamond M.S. Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob. Agents Chemother. 2007, 51:2396-2402.
40. Morrey J.D., Siddharthan V., Wang H., Hall J.O., Skirpstunas R.T., Olsen A.L., Nordstrom J.L., Koenig S., Johnson S., Diamond M.S. West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. J. Neurovirol. 2008, 14:152-163.
41. Nybakken G.E., Oliphant T., Johnson S., Burke S., Diamond M.S., Fremont D.H. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 2005, 437:764-769.
42. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., Gorlatov S., Mehlhop E., Marri A., Chung K.M., Ebel G.D., Kramer L.D., Fremont D.H., Diamond M.S. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 2005, 11:522-530.
43. Roehrig J.T., Corser J.A., Schlesinger M.J. Isolation and characterization of hybrid cell lines producing monoclonal antibodies directed against the structural proteins of Sindbis virus. Virology 1980, 101:41-49.
44. Roehrig J.T., Hombach J., Barrett A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Viral Immunol. 2008.
45. Roehrig J.T., Staudinger L.A., Hunt A.R., Mathews J.H., Blair C.D. Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann. NY Acad. Sci. 2001, 951:286-297.
46. Sbrana E., Xiao S.Y., Guzman H., Ye M., Travassos da Rosa A.P., Tesh R.B. Efficacy of post-exposure treatment of yellow fever with ribavirin in a hamster model of the disease. Am. J. Trop. Med. Hyg. 2004, 71:306-312.
47. Sbrana E., Xiao S.Y., Popov V.L., Newman P.C., Tesh R.B. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values. Am. J. Trop. Med. Hyg. 2006, 74:1084-1089.
48. Schlesinger J.J., Brandriss M.W. Antibody-mediated infection of macrophages and macrophage-like cell lines with 17D-yellow fever virus. J. Med. Virol. 1981, 8:103-117.
49. Schlesinger J.J., Brandriss M.W., Cropp C.B., Monath T.P. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J. Virol. 1986, 60:1153-1155.
50. Schlesinger J.J., Brandriss M.W., Monath T.P. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. Virology 1983, 125:8-17.
51. Schlesinger J.J., Chapman S. Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J. Gen. Virol. 1995, 76(Pt 1):217-220.
52. Schlesinger J.J., Walsh E.E., Brandriss M.W. Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies. J. Gen. Virol. 1984, 65(Pt 10):1637-1644.
53. Staples J.E., Gershman M., Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2010, 59:1-27.
54. Tesh R.B., Guzman H., da Rosa A.P., Vasconcelos P.F., Dias L.B., Bunnell J.E., Zhang H., Xiao S.Y. Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J. Infect. Dis. 2001, 183:1431-1436.
55. Thibodeaux B.A., Liss N.M., Panella A.N., Roehrig J.T. Development of a human-murine chimeric immunoglobulin M for use in the serological detection of human alphavirus antibodies. Clin. Vaccine Immunol. 2011, 18:2181-2182.
56. Thibodeaux B.A., Panella A.N., Roehrig J.T. Development of human-murine chimeric immunoglobulin G for use in the serological detection of human flavivirus and alphavirus antibodies. Clin. Vaccine Immunol. 2010, 17:1617-1623.
57. Thibodeaux B.A., Roehrig J.T. Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human flavivirus antibodies. Clin. Vaccine Immunol. 2009, 16:679-685.
58. Xiao S.Y., Zhang H., Guzman H., Tesh R.B. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J. Infect. Dis. 2001, 183:1437-1444.